vs
Good Times Restaurants Inc.（GTIM）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Good Times Restaurants Inc.的季度营收约是REGENXBIO Inc.的1.1倍（$32.7M vs $30.3M），Good Times Restaurants Inc.净利率更高（0.6% vs -221.3%，领先221.9%），REGENXBIO Inc.同比增速更快（43.0% vs -10.0%），Good Times Restaurants Inc.自由现金流更多（$1.2M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -0.7%）
美好时光餐饮公司（Good Times Restaurants Inc.）总部位于科罗拉多州戈尔登，是一家主打高端汉堡与冻奶油冰淇淋的快餐连锁品牌。截至2023年7月，该品牌共运营31家门店，较2015年的38家有所减少。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GTIM vs RGNX — 直观对比
营收规模更大
GTIM
是对方的1.1倍
$30.3M
营收增速更快
RGNX
高出53.0%
-10.0%
净利率更高
GTIM
高出221.9%
-221.3%
自由现金流更多
GTIM
多$54.0M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-0.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.7M | $30.3M |
| 净利润 | $181.0K | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 0.9% | -190.0% |
| 净利率 | 0.6% | -221.3% |
| 营收同比 | -10.0% | 43.0% |
| 净利润同比 | 10.4% | -31.2% |
| 每股收益（稀释后） | $0.02 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GTIMRGNX
| Q4 25 | $32.7M | $30.3M | ||
| Q3 25 | $37.0M | $29.7M | ||
| Q2 25 | $34.3M | $21.4M | ||
| Q1 25 | — | $89.0M | ||
| Q4 24 | $36.3M | $21.2M | ||
| Q3 24 | $35.8M | $24.2M | ||
| Q2 24 | $38.0M | $22.3M | ||
| Q1 24 | $35.4M | $15.6M |
净利润GTIMRGNX
| Q4 25 | $181.0K | $-67.1M | ||
| Q3 25 | $1.5M | $-61.9M | ||
| Q2 25 | $-624.0K | $-70.9M | ||
| Q1 25 | — | $6.1M | ||
| Q4 24 | $164.0K | $-51.2M | ||
| Q3 24 | $230.0K | $-59.6M | ||
| Q2 24 | $1.3M | $-53.0M | ||
| Q1 24 | $618.0K | $-63.3M |
毛利率GTIMRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率GTIMRGNX
| Q4 25 | 0.9% | -190.0% | ||
| Q3 25 | 3.3% | -176.3% | ||
| Q2 25 | -1.5% | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | 0.2% | -242.1% | ||
| Q3 24 | -0.3% | -256.6% | ||
| Q2 24 | 3.2% | -251.3% | ||
| Q1 24 | 1.8% | -408.8% |
净利率GTIMRGNX
| Q4 25 | 0.6% | -221.3% | ||
| Q3 25 | 4.0% | -208.3% | ||
| Q2 25 | -1.8% | -331.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | 0.5% | -241.3% | ||
| Q3 24 | 0.6% | -246.3% | ||
| Q2 24 | 3.5% | -237.7% | ||
| Q1 24 | 1.7% | -405.4% |
每股收益（稀释后）GTIMRGNX
| Q4 25 | $0.02 | $-1.30 | ||
| Q3 25 | $0.14 | $-1.20 | ||
| Q2 25 | $-0.06 | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | $0.02 | $-0.99 | ||
| Q3 24 | $0.01 | $-1.17 | ||
| Q2 24 | $0.12 | $-1.05 | ||
| Q1 24 | $0.06 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $33.2M | $102.7M |
| 总资产 | $82.5M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GTIMRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | $2.7M | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | $3.0M | $234.7M | ||
| Q3 24 | $3.9M | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | $4.0M | $338.7M |
股东权益GTIMRGNX
| Q4 25 | $33.2M | $102.7M | ||
| Q3 25 | $33.1M | $161.5M | ||
| Q2 25 | $31.6M | $213.7M | ||
| Q1 25 | — | $274.2M | ||
| Q4 24 | $32.4M | $259.7M | ||
| Q3 24 | $32.4M | $301.4M | ||
| Q2 24 | $32.3M | $348.3M | ||
| Q1 24 | $31.6M | $390.7M |
总资产GTIMRGNX
| Q4 25 | $82.5M | $453.0M | ||
| Q3 25 | $85.8M | $525.2M | ||
| Q2 25 | $86.9M | $581.0M | ||
| Q1 25 | — | $490.9M | ||
| Q4 24 | $89.5M | $466.0M | ||
| Q3 24 | $87.1M | $519.1M | ||
| Q2 24 | $90.1M | $569.4M | ||
| Q1 24 | $89.0M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $1.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | 3.8% | -174.0% |
| 资本支出强度资本支出/营收 | 0.6% | 1.7% |
| 现金转化率经营现金流/净利润 | 7.85× | — |
| 过去12个月自由现金流最近4个季度 | $-72.0K | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GTIMRGNX
| Q4 25 | $1.4M | $-52.3M | ||
| Q3 25 | $1.3M | $-56.0M | ||
| Q2 25 | $714.0K | $-49.3M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | $-518.0K | $-31.6M | ||
| Q3 24 | $394.0K | $-40.5M | ||
| Q2 24 | $3.2M | $-45.5M | ||
| Q1 24 | $1.8M | $-55.5M |
自由现金流GTIMRGNX
| Q4 25 | $1.2M | $-52.8M | ||
| Q3 25 | $735.0K | $-56.5M | ||
| Q2 25 | $-105.0K | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | $-1.9M | $-32.7M | ||
| Q3 24 | $-466.0K | $-40.9M | ||
| Q2 24 | $2.0M | $-46.0M | ||
| Q1 24 | $1.2M | $-56.0M |
自由现金流率GTIMRGNX
| Q4 25 | 3.8% | -174.0% | ||
| Q3 25 | 2.0% | -189.9% | ||
| Q2 25 | -0.3% | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | -5.3% | -154.2% | ||
| Q3 24 | -1.3% | -168.9% | ||
| Q2 24 | 5.3% | -206.2% | ||
| Q1 24 | 3.2% | -358.5% |
资本支出强度GTIMRGNX
| Q4 25 | 0.6% | 1.7% | ||
| Q3 25 | 1.4% | 1.7% | ||
| Q2 25 | 2.4% | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 3.9% | 5.1% | ||
| Q3 24 | 2.4% | 1.3% | ||
| Q2 24 | 3.2% | 2.1% | ||
| Q1 24 | 1.7% | 3.6% |
现金转化率GTIMRGNX
| Q4 25 | 7.85× | — | ||
| Q3 25 | 0.85× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | -3.16× | — | ||
| Q3 24 | 1.71× | — | ||
| Q2 24 | 2.44× | — | ||
| Q1 24 | 2.86× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTIM
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
